Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "psoriasis"

61 News Found

Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis
Biotech | February 08, 2022

Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis

Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane


Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
Biotech | January 22, 2022

Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study

UCB plans to submit regulatory applications in Q3 2022


Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis
Biotech | December 24, 2021

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis

Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000


U.S. FDA accepts Bristol Myers Squibb’s application for Deucravacitinib
Biotech | November 30, 2021

U.S. FDA accepts Bristol Myers Squibb’s application for Deucravacitinib

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)


Air pollution reduces life expectancy by eight years in India
News | November 25, 2021

Air pollution reduces life expectancy by eight years in India

India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution


Boehringer Ingelheim announces EMA marketing authorisation for spesolimab
Drug Approval | October 29, 2021

Boehringer Ingelheim announces EMA marketing authorisation for spesolimab

Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules


MediBuddy records a steep increase in dermatology consultation amongst youngsters
Startup | October 22, 2021

MediBuddy records a steep increase in dermatology consultation amongst youngsters

The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues


FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Drug Approval | October 20, 2021

FDA approves Cyltezo, the first interchangeable biosimilar to Humira

Second interchangeable biosimilar product approved by agency


Zydus Cadila receives final approval for Apremilast
Drug Approval | September 24, 2021

Zydus Cadila receives final approval for Apremilast

Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy


Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination